One interesting startup company I came across is Aureon, which developed a biomarker diagnostic, which predicts PSA recurrence and clinical disease progression in patients who have undergone radical prostatectomy. Samples are collected using needle biopsy.
The first diagnostic is Prostate Px, which looks at a set of seven protein prostate cancer biomarkers to fairly accurately predict PSA recurrence.
Among Aureon's founders are leading scientists at Memorial Sloan-Kettering Cancer Center, Yale Cancer Center, and Albert Einstein College of Medicine. he company is well financed and is rapidly moving ahead with its proastata diagnostic.
ww.aureon.com
Subscribe to:
Post Comments (Atom)
Signal Transduction Pathways
RTK, GPCR, GF, Cytokine, Wnt, Death Factors & Shh pathways
No comments:
Post a Comment